OUR OUR
40 th WORLD’S CLINICAL LABORATORY NEWS LEADER
V I S I T
YEAR YEAR
ISSN 1068-1760
Vol.40 No.1 • 2-3/2023
DAILY CLINICAL LAB NEWS
®
I
N
T
E
DNA Nanobait Test for Respiratory Viruses ollowing the arrival of the winter cold, flu and RSV season in the northern hemisphere, healthcare workers are required to take quick decisions about the treatment to be given to patients presenting themselves at hospitals or clinics. PCR (polymerase
F
R
N
A
T
I
O
New Platform Aims to Accelerate Diagnostic Tests for Future Pandemics he COVID-19 pandemic brought about a health crisis that highlighted severe fragilities within the healthcare sector, including lack of preparedness. In order to reduce vulnerability to future pandemics, there is a need for a large-scale, coordinated and
T
Cont’d on page 20
comprehensive health response. Now, a new project aims to establish a diagnostic assay platform that can enable a faster response time during emerging pandemics. A collaboration project, InfektoFlex, launched by Clickmer Systems (Manchester, UK; www. Cont’d on page 13
All-in-One System Cleans Up Blood Culture Contamination, Cuts Sepsis False Positives
N
A
L
Test Detects Predictive Biomarker for Dementia rgothioneine (ET) is a unique diet-derived compound discovered more than 100 years ago by Charles Tanret. However, it was only in 2005 when scientists discovered a transporter specific for ET that facilitates the uptake and accumulation of ET in the body. Now, a new study has revealed that low levels of ET in blood plasma may predict an increased risk of cognitive
E
Cont’d on page 14
First POC Test for ‘Insidious’ Malaria ach year, there are over 200 million cases of malaria and about 620,000 deaths across the world. Malaria is caused by the Plasmodium vivax parasite, which is transmitted to humans via the bite of an infected mosquito. The Plasmodium vivax parasite poses a challenge as it can remain dormant in the liver for years, but reawaken later to continue spreading the disease.
E
novel technology can drastically reduce blood culture contamination, thereby largely eliminating sepsis misdiagnosis, and hence preventing harmful antibiotic treatments as well as extended hospital stays.
A
See article on page 7
Cont’d on page 18 V
I
S
I
T
LINKXPRESS COM R E A D E R
S E R V I C E
®
P O R T A L
Renew/Start your Free Subscription Access Interactive Digital Magazine Instant Online Product Information:
AI Combined with Infrared Imaging Automatically Classifies Tumors n recent years, there has been a massive advancement in available treatments for colon cancer. To ensure treatments such as immunotherapies are effective, it is important to accurately diagnose the individual patient to provide specifically tailored treatments.
I
Cont’d on page 4
Thermo Fisher Completes Acquisition of UK’s Binding Site
Identify LinkXpress codes of 1 interest as you read magazine ®
on LinkXpress.com 2 toClick reach reader service portal Mark code(s) of interest on 3 LinkXpress ® inquiry matrix If your subscription is not renewed every 12 months your Free Subscription may be automatically discontinued
hermo Fisher Scientific Inc. (Waltham, MA; USA; www. thermofisher. com) has completed its acquisition of The Binding Site Group (Birmingham, UK; www.bindingsite.com) in an
T
all-cash transaction valued at GBP 2.3 billion, or USD 2.8 billion at the time of the transaction. Thermo Fisher had announced the agreement to acquire The Binding Site on October 31, 2022. Cont’d on page 25
INSIDE Clinical News . . . . . . 4 LabMedica EXPO . 6-20 IFCC News. . . . . . . . 21 Industry News .. . . . 25 Events Calendar. . 26 PUBLISHED IN COOPERATION WITH
International Federation of Clinical Chemistry and Laboratory Medicine
GLOBETECH >>> MEDIA <<<